ICCM IceCure Medical (ICCM) Q2 FY26 earnings call
IceCure Medical is experiencing an inflection point, with clinical and commercial strategies increasingly reinforcing each other. The company reported strong revenue growth and improved gross margin in the first half of 2026, driven by expanding U.S. commercial footprint and increasing utilization of ProSense systems. Progress on the CHoICE post-market study is viewed as an extension of commercialization, generating real-world evidence while supporting adoption and future reimbursement. The company maintains financial flexibility to invest in continued growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.